| Characteristic |
Value |
| Age |
38 - 82 (median, 65) |
| Gender |
M 48, F 8 |
| Stage |
Ⅱ 6, Ⅲ 4, ⅣA 39, ⅣB 6, ⅣC 1 |
| T stage |
T1 7, T2 17, T3 16, T4a 12, T4b 4 |
| N stage |
N0 9, N1 3, N2a 3, N2b 20, N2c 17, N3 4 |
| Concurrent chemotherapy |
total, 47 patients |
| TPF regimen |
28 |
| CDDP-based regimen |
44 |
| DOC-based regimen |
31 |
| None |
9 |
| Simultaneous thoracic EBRT for concurrent ESCC |
Yes 6, No 50 |
| CBVRR (%) |
1.8 - 17.1 (median, 6.8) |
| GTVRR (%) |
-9.8 to 86.8 (median, 52.7) |
| BWLR (%) |
-8.7 to 14.6 (median, 4.3) |
|
| Table 1: The patient characteristics of the oropharyngeal squamous cell carcinoma group (total, 56 patients). Abbreviation: TPF=Docetaxel, cisplatin and fluorouracil, CDDP=Cisplatin, DOC=Docetaxel, EBRT=External beam radiation therapy, ESCC=Esophageal squamous cell carcinoma, CBVRR=Cervical body volume reduction rate, GTVRR=Gross tumor volume reduction rate, BWLR=Body weight loss rate. |
